Immunotherapy drug delays recurrence in kidney cancer patients

(Dana-Farber Cancer Institute) Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.